Uprosertib — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	1	11	—	—	Jun 16, 2009
Cutaneous Melanoma	Phase2	Phase 2	0	1	—	—	Oct 8, 2013
Leukemia	Phase2	Phase 2	0	1	—	—	2013-10
Malignant Breast Neoplasm	Phase2	Phase 2	0	1	—	—

Curated evidence

Clinical evidence (4)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AKT1 E17K + BRAF V600EAKT1 BRAF2

Clinical trials

Trials with this intervention (11)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–11 of 11 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01979523	Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	active not recruiting	Phase 2	42	National Cancer Institute (NCI)NIH	3	Aug 6, 2026	clinicaltrials
NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	completed	Phase 1 / Phase 2

BRAF V600E + PTEN LossBRAF PTEN2
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID708 Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
Dabrafenib + UprosertibCombination	Melanoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID13116 Several BRAF V600E mutant melanoma cell lines (M249, M399, M397AR)) with PTEN mutation or loss of expression were among those sensitive to combination dabrafenib plus AKT inhibitor GSK2141795B, as mea… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic